Scintigraphy and radionuclide therapy with [Indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide

Italian Journal of Gastroenterology and Hepatology

Volumn 31, Issue 7 SUPPL. 2, 1999, Pages

  Krenning, E P ^a   Valkema, R ^a   Kooij, P P M ^a   Breeman, W A P ^a   Bakker, W H ^a   DeHerder, W W ^a   VanEijck, C H J ^a   Kwekkeboom, D J ^a   DeJong, M ^a   Pauwels, S ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Octreotide; Radionuclide; Radiotherapy; Somatostatin

Indexed keywords

PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT;

CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG PENETRATION; HUMAN; LYMPHOCYTE SUBPOPULATION; NEUROENDOCRINE TUMOR; PHASE 1 CLINICAL TRIAL; THROMBOCYTE COUNT; TUMOR SCINTISCANNING;

EID: 0032700471     PISSN: 11258055     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
2. Krenning EP, Kwekkeboom DJ, Pauwels S, Kvols LK, Reubi J-C. Somatostatin receptor scintigraphy. Nucl Med Ann 1995;1:1-50.
3. Virgolini I, Raderer M, Kurtaran, Angelberger P, Banyai S, Yang Q, et al. Vasoactive intestinal peptide receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 1994;331:1116-21.
4. Breeman WA, VanHagen MP, Visser-Wisselaar HA, van der Pluijm ME, Koper JW, Setyono-Han B,et al. In vitro and in vivo studies of substance P receptor expression in rats with the new analog [indium-111-DTPA-Arg1] substance P. J Nucl Med 1996;37:108-17.
5. 1]-octreotide. A case history. Ann NY Acad Sci 1994;733:496-506.
6. Krenning EP, Kooij PPM, Pauwels S, Breeman WAP, Postema PTE, DeHerder WW, et al. Somatostatin receptor: scintigraphy and radionuclide therapy. Digestion 1996;57 (Suppl. 1):57-61.
7. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. Ann Intern Med 1996;125:26-34.
8. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997;112:335-47.
9. Fjalling M, Andersson P, Forssell-Aronsson E, Gretarsdottir J, Johansson V, Tisell LE, et al. Systemic radionuclide therapy using indium-111-DTPA-D-Phel-octreotide in midgut carcinoid syndrome. J Nucl Med 1996;37:1519-21.
10. 1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation. Life Sci 1991;49:1583-91.
11. 3]octreotide. J Nucl Med 1992;33:652-8.
12. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res 1997;57:659-71.
13. Andersson P, Forssel-Aronsson E, Johanson V, Wangberg B, Nilsson O, Fjalling M, et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phel-octreotide. J Nucl Med 1996;37:2002-6.
14. 3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997;24:368-71.
15. Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, et al. Dotatoc: a powerful new tool for receptor-mediated radionuclide therapy. Eur J Nucl Med 1997;24:792-5.
16. DeJong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WAP, et al. Inhibition of renal uptake of Indium-111-DTPA-octreotide in vivo. J Nucl Med 1996;37:1388-92.
17. Bernard HF, Krenning EP, Breeman WAP, Rolleman EJ, Bakker WH, Visser TJ, et al. D-lysine reduction of Indium-111 octreotide and Yttrium-90 octreotide renal uptake. J Nucl Med 1997;38:1929-34.